Breakthrough in Cancer Gene Therapy: Targeted Delivery of Inflammation Inhibitors and miR138 Gene

Strategic Insights -

Researchers at China Pharmaceutical University have made a significant breakthrough in cancer gene therapy, developing a targeted delivery system that uses nanocrystals to deliver anti-inflammatory baicalein and miR138 gene therapy against pulmonary arterial hypertension (PAH). This innovative approach has shown promising results in improving pulmonary hemodynamics and reducing PA thickness by 20% through the promotion of PASMC apoptosis.

Key Takeaways:

  • The study aims to address the critical pathological feature of PAH, which is pulmonary artery remodeling caused by the hyperproliferation of PASMCs and perivascular inflammation.
  • The research team used a rod-shaped nanomedicine that targets the glucose transport-1 (GLUT-1) receptor, allowing for a 12-fold increase in pulmonary artery targeting versus free drug administration.
  • The system effectively promoted PASMC apoptosis, likely by strengthening the pathway of Bax/Bcl-2/Cas-3, leading to a 20% reduction in PA thickness.
  • In vivo efficacy in the monocrotaline (MCT) PAH model demonstrated significant improvements in pulmonary hemodynamics, including a 50% decrease in mean pulmonary artery pressure (mPAP), 61% increase in pulmonary artery acceleration time (PAAT), and 82% increase in cardiac output (CO).
  • The study suggests that targeted codelivery of inflammation inhibitors and anti-miR138 to PAs is a promising strategy for combating PAH.
  • The research team includes Wei He, Chenshi Lin, Chao Teng, and Bingbing Li from China Pharmaceutical University, with funding from the National Natural Science Foundation of China (NSFC) and the Science & Technology Commission of Shanghai Municipality (STCSM).

Statistics:

  • A 12-fold increase in pulmonary artery targeting versus free drug administration, achieved through the use of rod-shaped nanomedicines.
  • 20% reduction in PA thickness through the promotion of PASMC apoptosis.
  • 50% decrease in mean pulmonary artery pressure (mPAP).
  • 61% increase in pulmonary artery acceleration time (PAAT).
  • 82% increase in cardiac output (CO).
  • Funding from the National Natural Science Foundation of China (NSFC) and the Science & Technology Commission of Shanghai Municipality (STCSM).

Sources:

  • [Wei He et al., Anti-inflammatory drug-assisted microRNA gene therapy for effectively improving pulmonary hemodynamics, Chinese Chemical Letters, 2025;36(7)]
  • [China Pharmaceutical University, School of Pharmacy, Nanjing, 211198, People's Republic of China]
  • [Elsevier Science Inc, Ste 800, 230 Park Ave, New York, NY 10169, USA]
  • [National Natural Science Foundation of China (NSFC)]
  • [Science & Technology Commission of Shanghai Municipality (STCSM)]